Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Vaginal Neoplasms 1Lymphoma, Follicular 1Glioblastoma 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

lutetium Lu 177 dotatate 8Specimen Handling 5Magnetic Resonance Spectroscopy 5pembrolizumab 3olaparib 2fludarabine 2cabozantinib 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1repotrectinib 1peposertib 1pazopanib 1lenvatinib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT05724108 2026-05-13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡